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krengli@Purpose: To analyze the feasibility of intraoperative radiotherapy (IORT) in patients with high-risk prostate can-
cer and candidates for radical prostatectomy.
Methods andMaterials: A total of 38 patients with locally advanced prostate cancer were enrolled. No patients had
evidence of lymph node or distant metastases, probability of organ-confined disease >25%, or risk of lymph node
involvement >15% according to the Memorial Sloan-Kettering Cancer Center Nomogram. The IORTwas deliv-
ered after exposure of the prostate by a dedicated linear accelerator with beveled collimators using electrons of 9 to
12 MeV to a total dose of 10-12 Gy. Rectal dose was measured in vivo by radiochromic films placed on a rectal
probe. Adminstration of IORTwas followed by completion of radical prostatectomy and regional lymph node dis-
section. All cases with extracapsular extension and/or positive margins were scheduled for postoperative radio-
therapy. Patients with pT3 to pT4 disease or positive nodes received adjuvant hormonal therapy.
Results: Mean dose detected by radiochromic films was 3.9 Gy (range, 0.4–8.9 Gy) to the anterior rectal wall. The
IORT procedure lasted 31 min on average (range, 15–45 min). No major intra- or postoperative complications oc-
curred. Minor complications were observed in 10/33 (30%) of cases. Of the 27/31 patients who completed the post-
operative external beam radiotherapy, 3/27 experienced Grade 2 rectal toxicity and 1/27 experienced Grade 2
urinary toxicity.
Conclusions: Use of IORT during radical prostatectomy is feasible and allows safe delivery of postoperative exter-
nal beam radiotherapy to the tumor bed without relevant acute rectal toxicity.  2010 Elsevier Inc.
Intraoperative radiotherapy, Radical prostatectomy, Prostate cancer, Rectal dosimetry, Acute toxicity.INTRODUCTION
Radical prostatectomy or definitive radiotherapy are the com-
monly accepted standard treatments for localized prostate can-
cer achieving high rates of biochemical control. In contrast, no
treatmentmodality alone is able to achieve a satisfactory rate of
disease control in case of locally advanced/high risk disease.
Therefore, combination treatment including surgery, radiother-
apy, and hormonal therapymay be used to optimize the clinical
results (1, 2). Identification of patients at high risk for local fail-
ure may be obtained by using parameters such as high preoper-
ative PSA, Gleason score$7, clinical stage$T2c, and at least
two thirds positive biopsy cores (3, 4).
As far as radiation treatment is concerned, recent studies have
found a low alpha/beta ratio in prostate cancer (5), suggesting
that the administration of high doses per fraction may represent
a potential advantage for local control. However, studies usingt requests to: Marco Krengli, M.D., Radiotherapy, Univer-
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1073nonconventional dose/fractionation schedules should carefully
take into consideration the effects on the organs at risk.
Intraoperative radiotherapy (IORT) has been used for sev-
eral tumor locations as a boost or as sole radiation treatment
after or before tumor resection to improve local tumor control
(6). To date, very few studies on the use of IORT for prostate
cancer have been published using different technical ap-
proaches and showing promising preliminary results (7–10).
The purpose of the present study is to analyze the feasibility
of IORT and to describe the technical and dosimetric aspects in
patientswithhigh-riskprostate cancer andcandidates for radical
prostatectomy.METHODS AND MATERIALS
Between September 2005 and October 2008, 38 patients with lo-
cally advanced prostate cancer were included in the present study.Conflict of interest: none.
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Fig. 1. Rectal probe for in vivo dosimetry with four radiochromic
films on the surface to detect dose at the level of the anterior, poste-
rior, and laterals rectal walls.
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tution. Inclusion criteria were: Gleason score $7, clinical stage
$T2c, or PSA >10 ng/ml. Patients with evidence of lymph node
or distant metastases, probability of organ-confined disease
>25%, and risk of lymph node involvement >15% according to
the Memorial Sloan Kettering Cancer Center Nomogram (11)
were excluded. Age >76 years and diagnosis of inflammatory bowel
disease were other exclusion criteria. The main patient’s character-
istics are listed in Table 1.
All cases were preliminary discussed in a multidisciplinary meet-
ing with radiation oncologists, urologists, anaesthesiologists, phys-
icists, and radiation technologists to define the clinical and technical
aspects of the IORT procedure.
After induction of general anaesthesia and before starting the sur-
gical procedure, a rectal probe (12 cm in length and 2.5 cm in diam-
eter) was applied for dosimetry (Fig. 1). The IORT procedure started
after exposure of the anterior aspect of the prostate, section of the
pubo-prostatic ligaments, and control of the deep dorsal vein plexus.
First, the anterior–posterior prostate diameter and the distance from
prostate surface to the anterior rectal wall was measured by intrao-
perative ultrasound (US). Based on clinical and US parameters,
the appropriate collimator and beam energy were chosen to include
the prostate gland and the surrounding soft tissues with a suitable
margin for subclinical disease of 0.5 to 1 cm.
The IORT was delivered by a dedicated linear accelerator
(Mobetron, Intraop, Sunnyvale, CA) using an electron beam of 9
to 12 MeV to a total dose of 10 Gy in the first 3 patients and of
12 Gy in the following patients. The dose was prescribed at the
90% isodose. In all patients, rectal dose was measured in vivo by
four radiochromic films placed on the surface of the rectal probe
to detect the dose at the level of the anterior, posterior, and laterals
rectal walls.
Use of IORT was followed by radical prostatectomy and regional
lymph node dissection. All patients with evidence at pathology
examination of extracapsular extension and/or positive surgical
margins were scheduled for postoperative radiotherapy. Adjuvant
hormonal therapy was administered in patients with pT3 to pT4 dis-
ease or positive nodes. Indication for postoperative radiotherapy and
adjuvant hormonal therapy followed our institutional protocol,
based on the current literature that confirms long-term success rates
for high-risk patients with a multimodality treatment approach
(2, 12). Postoperative external beam radiotherapy was delivered to
prostate bed about 3 months after surgery by using three-dimen-
sional conformal radiotherapy with four to six customized beams
or dynamic arcs to a total dose of 46 to 50 Gy in 25 fractions
(2 Gy/fraction).Table 1. Preoperative characteristics of study patients
No. of patients 38
Age, y, median (range) 67 (56–76)
Karnofsky performance status, mean 90
Initial PSA (ng/ml), median (range) 39.5 (2.9-63.9)
Biopsy Gleason score
<7 5 (15%)
$7 33 (85%)
Clinical stage* (TNM 2002 classification)
#T2c 11 (29%)
>T2c 27 (71%)
Neoadjuvant hormone therapy 11 (29%)
* Based on digital rectal examination, transrectal ultrasound, and
abdominal computed tomography.RESULTS
The target volumewas irradiated by using beveled collima-
tors with 15 to 30 angles (median 30) and internal diameter
ranging from 4.5 cm to 6.5 cm (median 5.5 cm) (Table 2).
The mean prostate anterior–posterior diameter was 3.3 cm
(range, 2.2–5.7 cm). The mean depth of the anterior rectal
wall was 3.6 cm (range, 2.6–6.2 cm). The mean doses
detected by the radiochromic films were 3.9 Gy to the ante-
rior rectal wall, 1.1 Gy, and 1.4 Gy to the left and right rectal
walls respectively and 0.1 Gy to the posterior rectal wall. In
particular, the dose measured at the level of the anterior rectal
wall ranged from 0.4 Gy to 8.9 Gy (Fig. 2).
Mean overall treatment time (radical prostatectomy
+ IORT) was 236 min. The IORT procedure lasted on aver-
age 31 min (range, 15–45 min), and the duration decreased
over time with increasing experience. No major perioperative
complications occurred. The percentage of patients requiring
transfusion was 86% (33/38 patients). Minor complications
were observed in 10/33 (30%) of patients and included five
lymphoceles (16%) and two pelvic hematomas (6%). Four
lymphoceles were treated by percutaneous drainage because
of worsening abdominal pain and distension, and 1 patient re-
quired a surgical laparoscopic repair.
No patient experienced symptoms of acute rectal toxicity
in relation to IORT procedure.
In the 27/31 patients who completed the postoperative exter-
nal beam radiotherapy, 3/27 patients experiencedGrade 2 rectal
and 1/27 patients Grade 2 urinary toxicity according to the Ra-
diation Therapy OncologyGroup (RTOG) scale (13) (Table 3).
A total of 25 patients received adjuvant hormonal therapy.
Pathology data and margins status are reported in Table 4.
Mean follow-up was 18.2 months (range, 3–36 months). Me-
dian PSA 1 month after the procedure was 0.05 ng/ml (range,
0.003–5.1 ng/ml).
DISCUSSION
The rationale of IORT during radical prostatectomy is based
on the unsatisfactory results obtained by conventional
Table 2. Technical features of intraoperative radiotherapy
(IORT) procedure
IORT procedure No (%) of patients
Collimator size (cm)
4.5 1 (2.6%)
5.0 12 (31.6%)
5.5 15 (39.5%)
6.0 7 (18.4%)
6.5 2 (5.3%)
7.0 1 (2.6%)
Bevel angle
15 1 (2.6%)
30 37 (97.4%)
Energy (MeV)
9 9 (23.7%)
12 29 (76.3%)
Total dose (Gy)
10 3 (7.9%)
12 35 (92.1%)
Fig. 2. Maximum rectal dose measured in vivo by radiochromic
films placed on the surface of a rectal probe.
Table 4. Pathological staging according to the 2002 TNM
classification and surgical margins status
No. of patients 38
p Gleason Score
<7 2 (5%)
$7 36 (95%)
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cer. PatientswithT3 stage treatedbymultimodality approach in-
cluding radical prostatectomy have a 10-year relapse-free
survival rate even lower than 45% and a local failure rate higher
than 40% (4, 14).Our study focused on patientswith at least one
of the following risk factors: Gleason score$7, T clinical stage
$2c, or PSA >10 ng/ml. This population represents a subset of
patients at relatively high risk for biochemical failure and local
recurrence who are usually treated by surgery and/or radiother-
apy frequently associated with hormonal therapy (12, 15–17).
The percentage of positive surgical margins in our series
(71%) was relatively higher compared with that reported by
Orecchia et al. (9) and Saracino et al. (10), who observed
respectively 55% and 41% positive or close margins after
surgical resection. This may be explained by the slightly dif-
ferent patient population enrolled in these studies. In fact,
71% of cases were classified as cT3 in our series, whereas
only 55% and 41% of cases had this clinical stage in the series
by Orecchia et al. and Saracino et al. respectively (9, 10). The
use of the present approach may help us to find out if the
addition of IORT to external beam radiotherapy will allow
compensation for such relatively high rate of microscopical
residual disease.
As far as the technical aspects are concerned, we chose to
deliver IORT before prostate removal according to what was
donebyOrecchia et al. (9), but in contrast towhatwasproposed
by Saracino et al. (10) who performed the IORT procedure on
the urethral anastomosis just after radical prostatectomy. A po-
tential advantage of our approach is the optimization of the ir-Table 3. Acute toxicity after postoperative external beam
radiotherapy according to the Radiation Therapy Oncology
Group scale (13)
Toxicity
G0 patients,
n (%)
G1 patients,
n (%)
G2 patients,
n (%)
Gastrointestinal toxicity 22/27 (81.5%) 2/27 (7.5%) 3/27 (11%)
Genitourinary toxicity 25/27 (93%) 1/27 (3.5%) 1/27 (3.5%)radiated volume including prostate and surrounding tissues
possibly infiltrated by tumor cells. Using our technique, the
dose to the rectum can be limited because of the dose absorbed
by the prostate tissue. Finally, our approach can potentially
achieve a better irradiation of the prostatic apex that is fre-
quently site of recurrence.Conversely, a potential riskof the ap-
proach proposed by Saracino et al. (10) is the increase of long-
term complications such as strictures of the vesico-urethral
anastomosis or rectal damage because of the direct irradiation
of the anterior rectal wall.
To optimize the IORT procedure, a close cooperation with
the surgeon is essential. The urologist has to expose the prostate
and place a stitch on the bladder neck to facilitate the definition
of the target while positioning the collimator. Another crucial
aspect is the choice of the most appropriate diameter, bevel an-
gle, and beamenergy to deliver an adequate dose to the prostate
(i.e., the tumor) while sparing the underlying rectal wall. For
this purpose, we performed a US measure of the prostate
with special attention to the anterior–posterior diameter and
to the distancebetween the prostate surface and the anterior rec-
tal wall.
An advantage of the Mobetron machine used at our center
is the so-called ‘‘soft-docking.’’ In other terms, the collimator
is not directly connected with the nozzle but is positioned byPathological stage *
#T2c 14 (37%)
>T2c 24 (63%)
pN0 31 (82%)
pN1 7 (18%)
Positive surgical margins 27 (71%)
– focal 14 (51.8%)
– diffuse 13 (48.2%)
Negative surgical margins 11 (29%)
* According to the TNM 2002 classification.
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procedure, an air gap is maintained between the collimator
and the nozzle. This optimizes the pressure on the prostate
and helps in displacing the bladder outside the treatment
field, avoiding the risk of traumatizing the tissues with move-
ments of the machine.
Based on the intraoperative anatomical findings and the US
measurements, we generally chose 30 collimators 5 to 6 cm
in diameter and an energy level of the beam between 9 and 12
MeV energy to optimize the coverage of the prostate gland.
Rectal dosimetry was performed in all patients and showed
a mean dose at the level of the anterior rectal wall of 3.9 Gy
(range, 0.4–8.9 Gy). A relevant dose reduction was con-
stantly observed at the level of the posterior rectal wall,
meaning that the rectum was in the steep component of the
in depth dose–distribution curve. The variation of the dose
detected by rectal dosimetry in the anterior rectal wall in
the different patients may be explained by a number of fac-
tors: the different prostate diameters requiring different
beam energy, the different bevel angle of the collimator po-
sitioned on the prostate surface, and the two levels of pre-
scribed dose that in the beginning of the study was 10 Gy
and subsequently increased to 12 Gy. Our findings are con-
sistent with those reported by Orecchia et al. (9), in a series
of 11 patients treated with 10-MeV beam energy before pros-
tate removal, who found a mean rectal dose of 3.3 Gy with
a range of 2.5 to 4.4 Gy; these values are different from those
of Saracino et al. and Soriani et al. (10, 18) who reported
a rectal dose lower than 1% of the prescription dose in their
series undergoing irradiation after prostatectomy with a dif-
ferent technique. This measured low rectal dose may be re-
lated to the fact that in these series the collimator wasplaced near the prostate apex so that the isodose curves
included only the very lower aspect of the rectum. No data
about rectal dosimetry are reported in the articles from Japan
(7, 8, 19).
As far as surgical procedure, the percentage of patients
requiring blood transfusion was higher compared with lapa-
roscopic surgery but comparable to other experiences of open
surgery for locally advanced disease (20–22). We have to
take into account that the blood loss may be higher with
this approach because, during intraoperative irradiation, the
hemostatic control is not possible. Finally, the incidence of
perioperative complications after IORT was low and was
similar to that reported for radical prostatectomy alone in
the treatment of locally advanced prostate cancer (21). This
is probably due to the relatively short additional time required
for intraoperative irradiation compared to the overall time of
a typical radical prostatectomy and to the moderate dose of
radiation to the rectum as verified by in vivo dosimetry.CONCLUSION
In conclusion, IORT during radical prostatectomy is feasi-
ble. The technical approach described in the present article
allowed safe delivery of 12 Gy to the prostate and the sur-
rounding tissues and a further 46–50 Gy by postoperative ra-
diotherapy to the tumor bed without relevant acute rectal
toxicity. In terms of rectal dosimetry, the maximum dose
measured at the level of the anterior rectal wall ranged
from 0.4 Gy to 8.9 Gy, with a mean value of 3.9 Gy. Nomajor
postoperative complications were observed in our series.
Longer follow-up time is needed to assess the results in
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